Progress of anti‐vascular endothelial growth factor therapy for ocular neovascular disease: benefits and challenges
Progress of anti‐vascular endothelial growth factor therapy for ocular neovascular disease: benefits and challenges
复制标题
DOI：
10.3760/cma.j.issn.0366-6999.20140017
复制
发表时间：
2014-04
影响因子：
6.1
通讯作者：
Jianjiang Xu;Li Yimin;Hong Jiaxu
中科院分区：
文献类型：
--
作者：
Jianjiang Xu;Li Yimin;Hong Jiaxu
目的综述抗血管内皮生长因子（VEGF）治疗眼部血管新生的临床研究进展，探讨其治疗的益处和挑战。检索了Pubmed、Embase和科克伦图书馆的数据源，没有语言和出版年份的限制。研究选择回顾了过去十年中在医学会议上发表的临床试验和病例研究，以及在同行评议文献中发表的临床试验和病例研究。结果抗VEGF药物在治疗眼部新生血管方面表现出巨大的潜力和有希望的结果，尽管其中一些仍然作为标签外药物使用。玻璃体内注射抗VEGF药物可能伴有毁灭性的眼部或全身并发症，需要对成人和儿童人群进行密切监测。未来的方向应该集中在进行更精心设计的大规模对照试验，促进持续的作用时间，开发更安全和更有效的抗VEGF药物。结论抗VEGF治疗已被证明对治疗前部和后部新生血管性眼部疾病均有益。然而，有必要探索更安全、更实惠的抗血管生成药物和治疗方案。
Objective This review aims to summarize the progress of current clinical studies in ocular angiogenesis treated with anti‐vascular endothelial growth factor (VEGF) therapy and to discuss the benefits and challenges of the treatment. Data sources Pubmed, Embase and the Cochrane Library were searched with no limitations of language and year of publication. Study selection Clinical trials and case studies presented at medical conferences and published in peer‐reviewed literature in the past decade were reviewed. Results Anti‐VEGF agents have manifested great potential and promising outcomes in treating ocular neovascularization, though some of them are still used as off‐label drugs. Intravitreal injection of anti‐VEGF agents could be accompanied by devastating ocular or systemic complications, and intimate monitoring in both adult and pediatric population are warranted. Future directions should be focused on carrying out more well‐designed large‐scale controlled trials, promoting sustained duration of action, developing safer and more efficient generation of anti‐VEGF agents. Conclusions Anti‐VEGF treatment has proved to be beneficial in treating both anterior and posterior neovascular ocular diseases. However, more safer and affordable antiangiogenic agencies and regimens are warranted to be explored.